Pasar al contenido principal

FOMENTAR LA INMUNIDAD FRENTE A TUMORES PANCREATICOS CON ADENOVIRUS ONCOLITICOS CAPACES DE INDUCIR MUERTE CELULAR POR "IMMUNOGENIC SURRENDER" Y BLOQUEO DE LA INMUNOSUPRESION.

PID2023-146637OB-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ DE RECERCA CLÍNIC BARCELONA-INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment

  • Parés, Marta
  • Pallaruelo-Santamaría, Víctor
  • Fillat, Cristina
  • Martínez-Latorre, Javier|||0000-0001-5421-5371
  • Candela-Noguera, Vicente
  • Soriano-Teruel, Paula
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant malignancies, with limited efficacy to conventional treatments such as surgical resection or chemotherapy. This clinical scenario underscores the need for novel therapeutic strategies. The development of multifunctional platforms capable of targeting tumors through multiple mechanisms offers an innovative strategy to overcome this challenge. Lipid nanoparticles (LNPs) offer a versatile platform capable of efficiently delivering genetic material. Moreover, through surface functionalization it is feasible to improve LNP performance optimizing therapeutic outcomes in a single formulation. Here, we explored a dual functionalization strategy of the LNP for tumor targeting and tumor remodeling to improve treatment efficacy. LNPs were designed for delivering reporter DNA plasmid or mRNA into the PDAC cellular models Capan-2 and PANC-1. The DNA plasmid contains a pancreatic cancer-specific chimeric promoter for transcriptional specificity to PDAC cells. Besides, LNPs were functionalized with folate and an anti-CD47 antibody to both target the folate receptor in PDAC cells and block CD47-mediated immune evasion. Both pDNA and mRNA LNPs targeted PDAC cells in a dose-dependent manner, with mRNA-LNPs demonstrating more efficient transfection. Notably, LNPs functionalized with the anti-CD47 antibody increased phagocytosis in vitro, and promoted an inflammatory phenotype of M1-like macrophages in mouse Capan-2 xenografts. This combinatorial design of the formulated LNP represents an innovative therapeutic strategy and opens future perspectives in the search for effective treatments for PDAC. Keywords: Lipid nanoparticles; Immunotherapy; ACD47; Folate; Macrophages; Pancreatic cancer, This research was supported by European Union s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020- 119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovacion ¿ and by the European Regional Development Fund A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from la Caixa Foundation under agreement LCF/PR/ SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models

  • Otero, Marc
  • Estrany Castillo, Francesc
  • Pembaur, Daniel
  • Gracia Batllori, Albert
  • Parés, Marta
  • Díaz Permanyer, Adrià
  • Brugada-Vilà, Pau
  • Fornaguera, Cristina
  • Cascante, Anna
  • Borrós, Salvador
  • Kreppel, Florian
  • Fillat, Cristina
Enhancing the safety and efficacy of systemically administered oncolytic adenoviruses remains a significant challenge to achieve effective targeting of primary tumors and disseminated disease. Intravenous administration exposes viral particles to various blood components interfering with their therapeutic activity. To protect adenoviruses from the inactivating factors we developed a shielding strategy based on a nanoparticle formulation reactive to a specific-site in the hexon hypervariable region 1. We propose a novel coating approach based on the combination of a bioresponsive oligopeptide-modified poly(β-aminoester)s (OM-PBAE-CRRR) and an irreversible linear PEG polymer with protruding ends to shield the oncolytic adenovirus AdNuPARc-E (PEPB). The formulated virus displays a slight delay in the transduction and replicative capacity at early time points that normalizes in a few days. Interestingly, similar oncolytic efficacy to the naked virus was observed in vitro, with enhanced antitumor effect in vivo in a pancreatic cancer model. In accordance, PEPB showed significantly enhanced pharmacokinetics and increased liver and tumor transduction in the xenograft model. In the presence of neutralizing antibodies (NAbs) coated viral particles maintained the infectivity and the replication capacity. Notably, in pre-immunized immunocompetent mice, protection from NAbs resulted in a higher viral accumulation in tumors than in the liver and was associated with significant antitumor activity. In summary, our findings indicate that the proposed formulation PEPB —the oncolytic adenovirus AdNuPARc-E site-specifically shielded with OM-PBAE-CRRR/PEG — offers a promising approach to improve tumor targeting after systemic administration, even in the presence of pre-existing neutralizing antibodies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models

  • Otero, Marc
  • Estrany Castillo, Francesc
  • Pembaur, Daniel
  • Gracia Batllori, Albert
  • Parés, Marta
  • Díaz Permanyer, Adrià
  • Brugada-Vilà, Pau
  • Fornaguera, Cristina
  • Cascante, Anna
  • Borrós, Salvador
  • Kreppel, Florian
  • Fillat, Cristina
Enhancing the safety and efficacy of systemically administered oncolytic adenoviruses remains a significant challenge to achieve effective targeting of primary tumors and disseminated disease. Intravenous administration exposes viral particles to various blood components interfering with their therapeutic activity. To protect adenoviruses from the inactivating factors we developed a shielding strategy based on a nanoparticle formulation reactive to a specific-site in the hexon hypervariable region 1. We propose a novel coating approach based on the combination of a bioresponsive oligopeptide-modified poly(β-aminoester)s (OM-PBAE-CRRR) and an irreversible linear PEG polymer with protruding ends to shield the oncolytic adenovirus AdNuPARc-E (PEPB). The formulated virus displays a slight delay in the transduction and replicative capacity at early time points that normalizes in a few days. Interestingly, similar oncolytic efficacy to the naked virus was observed in vitro, with enhanced antitumor effect in vivo in a pancreatic cancer model. In accordance, PEPB showed significantly enhanced pharmacokinetics and increased liver and tumor transduction in the xenograft model. In the presence of neutralizing antibodies (NAbs) coated viral particles maintained the infectivity and the replication capacity. Notably, in pre-immunized immunocompetent mice, protection from NAbs resulted in a higher viral accumulation in tumors than in the liver and was associated with significant antitumor activity. In summary, our findings indicate that the proposed formulation PEPB —the oncolytic adenovirus AdNuPARc-E site-specifically shielded with OM-PBAE-CRRR/PEG — offers a promising approach to improve tumor targeting after systemic administration, even in the presence of pre-existing neutralizing antibodies., info:eu-repo/semantics/publishedVersion